Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Sell
27
ASTH Quote, Financials, Valuation and Earnings
Last price:
$30.9400
Seasonality move
:
13.11%
Day range:
$29.2000 - $30.4400
52-week range:
$23.1200 - $63.2000
Dividend yield:
0%
P/E ratio:
34.15x
P/S ratio:
0.72x
P/B ratio:
1.93x
Volume:
279.6K
Avg. volume:
324.7K
1-year change:
-18.81%
Market cap:
$1.4B
Revenue:
$2B
EPS (TTM):
$0.89
Analysts' Opinion
-
Consensus RatingAstrana Health has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $50.5000, Astrana Health has an estimated upside of 66.17% from its current price of $30.3900.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.0000 representing -18.46% downside risk from its current price of $30.3900.
Fair Value
-
According to the consensus of 12 analysts, Astrana Health has 66.17% upside to fair value with a price target of $50.5000 per share.
ASTH vs. S&P 500
-
Over the past 5 trading days, Astrana Health has underperformed the S&P 500 by -10.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Astrana Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astrana Health has grown year-over-year revenues for 12 quarters straight. In the most recent quarter Astrana Health reported revenues of $665.2M.
Earnings Growth
-
Astrana Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Astrana Health reported earnings per share of -$0.15.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
0.72x
EV / EBIT:
11.62x
EV / Revenue:
0.65x
PEG ratio (5yr expected):
0.78x
EV / Free cash flow:
29.96x
Price / Operating cash flow:
33.01x
Enterprise value / EBITDA:
9.33x
Gross Profit (TTM):
$271.4M
Return On Assets:
3.57%
Net Income Margin (TTM):
2.12%
Return On Equity:
9.13%
Return On Invested Capital:
4.97%
Operating Margin:
0.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.4B | $2B | $353M | $665.2M | |
| Gross Profit | $199.5M | $215M | $271.4M | $39M | $50.5M | |
| Operating Income | $104.3M | $84.6M | $89.4M | -$3.9M | $720K | |
| EBITDA | $112.1M | $123.7M | $141.8M | $11.2M | $14.3M | |
| Diluted EPS | $1.00 | $1.29 | $0.89 | $0.26 | -$0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $338.6M | $404.5M | $428.1M | $461.5M | $638.5M | |
| Total Assets | $817.5M | $867.4M | $966.2M | $933.4M | $1.4B | |
| Current Liabilities | $115M | $114.7M | $148.6M | $218.7M | $365.6M | |
| Total Liabilities | $372.3M | $356.7M | $407.7M | $522.6M | $840.7M | |
| Total Equity | $445.1M | $510.6M | $558.5M | $410.8M | $514.2M | |
| Total Debt | $241.1M | $183.7M | $204M | $278.4M | $434.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $82.1M | $68.2M | $52.2M | $19.3M | -$10.9M | |
| Cash From Investing | -$7.1M | -$65.5M | -$192.4M | -$11.4M | -$33.3M | |
| Cash From Financing | -$20.1M | $3.4M | $135.1M | $12M | -$15.3M | |
| Free Cash Flow | $59.2M | $39.7M | $44.2M | $12.2M | -$13.5M | |
ASTH
Sector
Market Cap
$1.4B
$34.9M
Price % of 52-Week High
48.09%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
-2.92%
-0.82%
1-Year Price Total Return
-18.81%
-40.42%
Beta (5-Year)
1.044
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
9.35%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$32.1450
200-day SMA
Sell
Level
$42.6674
Bollinger Bands (100)
Sell
Level
29.8671 - 38.5671
Chaikin Money Flow
Buy
Level
3.6M
20-day SMA
Sell
Level
$31.2190
Relative Strength Index (RSI14)
Sell
Level
45.4151
ADX Line
Sell
Level
16.5984
Williams %R
Neutral
Level
-57.713
50-day SMA
Sell
Level
$32.0371
MACD (12, 26)
Sell
Level
-0.0063
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
24.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3951)
Buy
CA Score
(Annual)
Level (1.0496)
Sell
Beneish M-Score
(Annual)
Level (-1.0901)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.9077)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company’s three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Stock Forecast FAQ
In the current month, ASTH has received 9 Buy ratings 3 Hold ratings, and 0 Sell ratings. The ASTH average analyst price target in the past 3 months is $50.5000.
-
Where Will Astrana Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astrana Health share price will rise to $50.5000 per share over the next 12 months.
-
What Do Analysts Say About Astrana Health?
Analysts are divided on their view about Astrana Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astrana Health is a Sell and believe this share price will drop from its current level to $36.0000.
-
What Is Astrana Health's Price Target?
The price target for Astrana Health over the next 1-year time period is forecast to be $50.5000 according to 12 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ASTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astrana Health is a Buy. 9 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASTH?
You can purchase shares of Astrana Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astrana Health shares.
-
What Is The Astrana Health Share Price Today?
Astrana Health was last trading at $30.9400 per share. This represents the most recent stock quote for Astrana Health. Yesterday, Astrana Health closed at $30.3900 per share.
-
How To Buy Astrana Health Stock Online?
In order to purchase Astrana Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 9.37% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 1.69% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 1.81% over the past day.
